Xiuning Le, Deputy Section Chief of Thoracic Medical Oncology at MD Anderson Cancer Center, shared a post on X about a paper she co-authored with colleagues published in the Journal of Clinical Oncology:
“New online: JCO
Sunvozertinib becomes the 1st TKI approved (FDA, 2025) for EGFR ex20ins NSCLC.
- ORR: 45–47%
- DoR: 11–13.8 mo
- Similar efficacy in near- vs. far-loop insertions
- ORR 25% in pre-treated with Amivantamab
Sunvozertinib in Platinum-Pretreated NSCLC (WU-KONG1B) | Journal of Clinical Oncology.”
Title: Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non–Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)
Authors: James Chih-Hsin Yang, Mengzhao Wang, Ludovic Doucet, Yun Fan, Dongqing Lv, Meili Sun, Dingzhi Huang, Laurent Greillier, David Planchard, Qunying Hong, Julien Mazieres, Enriqueta Felip, Xingya Li, Ying Hu, Jian Fang, Lyudmila Bazhenova, François Ghiringhelli, Manuel Angel Cobo Dols, Luis Paz-Ares Rodriguez, Alessandra Bearz, Bruna Pellini, Yu Jung Kim, Joaquim Bosch-Barrera, Byoung-Yong Shim, Yung-Hung Luo, Marcello Tiseo, Tsung-Ying Yang, Enric Carcereny, Regan M. Memmott, Gerard Zalcman, Javier de Castro Carpeno, Vincenzo Di Noia, Hector Soto Parra, Guillermo Streich, Dae Ho Lee, Elaine Shum, Ji-Youn Han, Jesus Corral Jaime, Daniel Brungs, Thomas John, Manolo D’Arcangelo, Andres Barba Joaquin, Geoffrey Liu, Lorenzo Antonuzzo, Gonzalo Fernández Hinojal, Xiuning Le, Li Zheng, Pasi A. Jänne
You can read the Full Article in the Journal of Clinical Oncology.
More posts featuring Xiuning Le.